Appendix 1

Pregnancy Identification Algorithm

We used the following procedure to identify unique pregnancies in Oregon Medicaid, Emergency Medicaid and Emergency Medicaid Plus claims data from January 1, 2003 through October 1, 2015.

- 1. Limit sample to women ages 12-51 at the time of the claim
- 2. Identify pregnancy-related claims using *International Classification of Diseases*, *Ninth Revision* ±*ICD-9* and *Current Procedural Terminology* ±*CPT*
- 3. Score claims using ICD-9 diagnosis, *Current Procedure Terminology* ±CPT and ICD-9 procedure codes that could occur only at the end of a pregnancy episode and indicate the outcome type ±e.g. spontaneous abortion versus live birth. We refer to these as "outcome codes". Use the following hierarchy for dating each potential day that marks the end of a pregnancy episode:
 - a. a day is coded with a score of "10" if there are any claims with an ICD-9 procedure outcome code on that day
 - b. a day is coded with a score of "10" if there are claims with outcome codes from at least two different categories ±ICD-9 diagnosis, CPT or ICD-9 procedures on that day
 - c. a day is coded with a score of "5" if there are only claims with outcome codes from either the ICD-9 diagnosis or the CPT category, but there are four or more such claims on that day
 - d. a day is coded with a score of "1" if there are only claims with outcome codes from either the ICD-9 diagnosis or the CPT category, and there are three or fewer such claims on that day
 - e. Hierarchically favoring higher scores, establish dates for end of pregnancy episodes with a score of 10, then a score of 5, then a score of 1.
 - f. Use the identified dates generated with $\pm e$ to group claims by pregnancy episode.
 - i. Estimate gestational age using a previously published algorithm based on national median gestational age by outcome type:¹
 - 1. Ectopic pregnancy = 8 weeks
 - 2. Spontaneous abortion = 10 weeks
 - 3. The rapeutic abortion = 10 weeks
 - 4. Preterm birth = 34 weeks
 - 5. Stillbirth = 28 weeks
 - 6. Full-term birth = 40 weeks

- 7. Preterm birth = 34 weeks
- 8. Unknown abortion = 10 weeks
- 9. Early Loss unknown type = 10 weeks
- 10. Trophoblastic pregnancy = 8 weeks
- g. Subtract gestational age from outcome date to group claims as relating to a single pregnancy episode if they fall within the date range. Include claims falling in a prespecified time period after the claim as follow up or postpartum care
 - 1. Ectopic pregnancy = 4 weeks
 - 2. Spontaneous abortion = 4 weeks
 - 3. The rapeutic abortion = 4 weeks
 - 4. Preterm birth = 8 weeks
 - 5. Stillbirth = 8 weeks
 - 6. Full-term birth = 8 weeks
 - 7. Preterm birth = 8 weeks
 - 8. Unknown abortion = 4 weeks
 - 9. Early Loss unknown type = 4 weeks
 - 10. Trophoblastic pregnancy = 4 weeks
- h. Initially, exclude days with pregnancy outcomes that would have overlapping time windows for the pregnancy episodes.
- i. After the first, non-overlapping classification, search among the remaining days with outcome code claims for scores of 10 and then scores of 5. Designate additional pregnancy episode outcomes if they are separated from preceding or subsequent outcomes by a minimum number of weeks based on biological feasibility.
 - 1. Ectopic pregnancy = 4 week prior, 4 weeks following
 - 2. Spontaneous abortion = 4 week prior, 4 weeks following
 - 3. Therapeutic abortion = 4 week prior, 4 weeks following
 - 4. Preterm birth = 20 weeks prior, 8 weeks following
 - 5. Stillbirth = 20 weeks prior, 8 weeks following
 - 6. Full-term birth = 20 weeks prior, 8 weeks following
 - 7. Preterm birth = 20 weeks prior, 8 weeks following

- 8. Unknown abortion = 4 week prior, 4 weeks following
- 9. Early Loss unknown type = 4 week prior, 4 weeks following
- 10. Trophoblastic pregnancy = 4 week prior, 4 weeks following

Overall of 586,060 days that had one or more outcome codes, 98.5% of days ended up being associated with a pregnancy episode. Of the 577,459 days associated with a pregnancy episode, about 99.3% were identified in the first non-overlapping classification.


Appendix 2

Greedy matching algorithm for women and infants

The following procedure was used to match pregnancies to infants in the claims data.

- 1. Identify pregnancy outcomes that would result in a live birth among women in the claims data aged 12-51 ±as detailed above.
- 2. Identify claimants aged 0 in the claims database.
- 3. Use three variables to find a first set of matches: scrambled Household ID, the date of the birth based on the end of the pregnancy period, and the infant date of birth.
 - a. Date of birth must match the estimated date of the pregnancy outcome ± 2 days
- 4. For pregnancies that remain unmatched, search for a matching infant among the remaining cohort using the a matching date ± 2 days for the estimated date of the birth based on the end of the pregnancy and the infant date of birth, enrollment zip code of the claimants ±mother and infant, service zip codes of the claimants ±mother and infant, race and ethnicity ±mother and infant.
- 5. In the matched data we then dropped multiple birth.
- 6. The final match rate was 77% overall including 83% for pregnancies under Emergency Medicaid, 82% for pregnancies under Emergency Medicaid Plus, and 76% for pregnancies under Medicaid. The match rate was fairly stable over the years with a minimum match rate of 74% and a maximum match rate of 81% and a standard deviation of the match rate across years of 0.02. This temporal stability pattern was roughly similar for all three insurance groups.

Appendix 3.



Appendix 4: Start Date of Emergency Medicaid Plus by County

County:	Start Date:	
Deschutes	4/1/08	
Multnomah	4/1/08	
Jackson	10/1/09	
Benton	10/1/09	
Clackamas	10/1/09	
Hood River	10/1/09	
Lane	1/1/11	
Wasco	7/1/11	
Columbia	7/1/11	
Crook	7/1/11	
Union	7/1/11	
Jefferson	7/1/11	
Morrow	7/1/11	
Douglas	7/1/11	
Umatilla	4/1/12	
Gilliam	10/1/13	
Wheeler	10/1/13	
Curry	10/1/13	
Klamath	10/1/13	
Grant	10/1/13	
Clatsop	10/1/13	
Lake	10/1/13	
Polk	10/1/13	
Sherman	10/1/13	
Marion	10/1/13	
Coos	10/1/13	
Washington	10/1/13	
Tillamook	10/1/13	
Malheur	10/1/13	
Yamhill	10/1/13	
Wallowa	10/1/13	
Baker	10/1/13	
Josephine	10/1/13	
Lincoln*	10/1/13	
Linn	10/1/13	
Harney	10/1/13	

Source: Administrative records and personal communication with the Oregon Health Authority.

*Lincoln county initially participated in the Emergency Medicaid Plus program from October to December 2009 but then ended its participation until October 2013.

Swartz JJ, Hainmueller J, Lawrence J, Rodriguez MI. Expanding prenatal care to unauthorized immigrant women and the effects on infant health. Obstet Gynecol 2017; 130.

The authors provided this information as a supplement to their article.

Description of Appendixes 5-8

Measures

We examined outcomes related to utilization of health services for mothers and infants, as well as health outcomes related to mothers and infants. We used ICD-9, CPT and National Drug Codes \pm NDC.

Appendix 5. Codes for Outcome Measures for Immigrant Women

Measure	ICD-9	CPT	NDC#
Number of prenatal	V22.x, V23.x		
visits*			
Preterm delivery ⁺	644.21		
TdAP vaccine		90715, 90658, 90654,	
		90667, 90661, 90630,	
		90662, 90688, 90656,	
		90673, 90686, 90471,	
		90472	
Rhogam administration		G8809, G8810, J2788,	0562780501,
		J2790, J2791, J2792,	0562780508,
		90384, 90385, 90386	0562780525,
		, ,	0562780601,
			0562780605,
			0562780625,
			4420630001,
			4420630010
Oral glucose tolerance		82947, 82950, 82951,	
testing		82952	

^{*}National Drug Codes

^{*} Visits were defined as claims from distinct days of service as multiple claims were often associated with a single visit including primary, secondary and tertiary diagnosis codes associated with the claim.

⁺ Preterm birth was identified using both maternal and infant ICD-9 codes.

Appendix 6. Codes for Outcome Measures for Infants

Measure	ICD-9 codes
Number of Well-child visits*	V20.x
Preterm delivery ⁺	765.x, 774.2x, 776.x
Low birthweight [±]	764.x and 765.x

^{*} Visits were defined as claims from distinct days of service as multiple claims were often associated with a single visit including primary, secondary and tertiary diagnosis codes associated with the claim.

Screening and vaccines were identified using a comprehensive vaccine list from the Centers for Disease Control and Prevention, a Preventive Medicine Coding Fact Sheet from the American Academy of Pediatrics, and a manual search.^{2,3} The list included the following components:

⁺ Preterm birth was identified using both maternal and infant ICD-9 codes.

[±] Coding sections that indicate weight listed with the fifth digit used for weight category.

Appendix 7. Codes for Screenings for Infants

Screenings	CPT
Vision screening	99173, 99174
Hearing screening	92551, 92552, 92567
Developmental Screening	96110
Lead screening	83655

Appendix 8. Codes for Vaccines

Vaccina	СРТ
Vaccine	
Immune globulin ±IG, human, for intramuscular use	90281
Immune globulin ±IGIV, human, for intravenous	90283
Botulinum antitoxin, equine, any route	90287
Cytomegalovirus immune globulin ±CMV-IGIV,	90291
human, for intravenous use	
Diphtheria antitoxin, equine, any route	90296
Hepatitis B immune globulin ±HBIG, human, for intramuscular use	90371
Rabies immune globulin ±RIG, human, for intramuscular and/or subcutaneous use	90375
Rabies immune globulin, heat-treated ±RIG-HT, human, for intramuscular and/or subcutaneous use	90376
Respiratory syncytial virus immune globulin ±RSV-IgIM, for intramuscular use, 50 mg, each	90378
Respiratory syncytial virus immune globulin ±RSV-IGIV, human, for intravenous use	90379
Tetanus immune globulin ±TIG, human, for intramuscular use	90389
Vaccinia immune globulin, human, for intramuscular use	90393
Varicella-zoster immune globulin, human, for intramuscular use	90396
H1N1 immunization administration ±intramuscular, intranasal, including counseling when performed	90470
Adenovirus vaccine, type 4, live, for oral use	90476
Adenovirus vaccine, type 7, live, for oral use	90477
Anthrax vaccine, for subcutaneous use	90581
Bacillus Calmette-Guerin vaccine ±BCG for tuberculosis, live, for percutaneous use	90585
Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2 dose schedule, for intramuscular	90620
Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use	90621

The authors provided this information as a supplement to their article.

Cholera vaccine live, adult dosage, 1 dose	90625
schedule, for oral use	00620
Influenza virus vaccine, quadrivalent ±IIV4, split virus, preservative free, for intradermal use	90630
Hepatitis A vaccine, adult dosage, for	90632
intramuscular use	90032
Hepatitis A vaccine, pediatric/adolescent dosage-2	90633
dose schedule, for intramuscular use	90033
Hepatitis A vaccine, pediatric/adolescent dosage-3	90634
dose schedule, for intramuscular use	70034
Hepatitis A and hepatitis B ±HepA-HepB, adult	90636
dosage, for intramuscular use	70030
Meningococcal conjugate vaccine, serogroups C	90644
& Y and Hemophilus influenza B vaccine	70044
±MenCY-Hib	
Haemophilus influenza b vaccine ±Hib, HbOC	90645
conjugate ±4 dose schedule, for intramuscular use	700.5
Haemophilus influenza b vaccine ±Hib, PRP-D	90646
conjugate, for booster use only, intramuscular use	
Haemophilus influenza b vaccine ±Hib, PRP-	90647
OMP conjugate ±3 dose schedule, for	
intramuscular use	
Haemophilus influenza b vaccine ±Hib, PRP-T	90648
conjugate ±4 dose schedule, for intramuscular use	
Human Papilloma virus ±HPV vaccine, types 6,	90649
11, 16, 18 ±quadrivalent 3 dose schedule, for	
intramuscular use	
Human Papilloma virus ±HPV vaccine, types 16,	90650
18, bivalent, 3 dose schedule, for intramuscular	
use	
Human Papillomavirus vaccine types 6, 11, 16,	90651
18, 31, 33, 45, 52, 58, nonavalent ±HPV	
Influenza virus vaccine, inactivated, subunit,	90653
adjuvanted for IM us	
Influenza virus vaccine, split virus, preservative	90654
free, for intradermal use	00.577
Influenza virus vaccine, trivalent, split virus,	90655
preservative free, for children 6-35 months of age,	
for intramuscular use	00656
Influenza virus vaccine, trivalent, split virus,	90656
preservative free, for use in individuals 3 years of	
age and above, for intramuscular use Influenza virus vaccine, trivalent, split virus, for	90657
children 6-35 months of age, for intramuscular	70031
use	
usc	

The authors provided this information as a supplement to their article.

Influenza virus vaccine, trivalent, split virus, for	90658
use in individuals 3 years of age and above, for intramuscular use	
Influenza virus vaccine, whole virus, for	90659
intramuscular or jet injection use	
Influenza virus vaccine, trivalent, live, for	90660
intranasal use	
Influenza virus vaccine, derived from cell	90661
cultures, subunit, preservative and antibiotic free,	
for intramuscular use	00662
Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased	90662
antigen content, for intramuscular use	
Influenza virus vaccine, pandemic formulation,	90663
H1N1	70003
Influenza virus vaccine, pandemic formulation,	90664
live, for intranasal use	
Lyme disease vaccine, adult dosage, for	90665
intramuscular use	
Influenza virus vaccine, pandemic formulation,	90666
split-virus, preservative free, for intramuscular use	
Influenza virus vaccine, pandemic formulation,	90668
split-virus, for intramuscular use	00.00
Pneumococcal conjugate vaccine, polyvalent, for	90669
children under five years, for intramuscular use	90670
Pneumococcal conjugate vaccine, 13 valent, for intramuscular use	90670
Influenza virus vaccine, quadrivalent ±LAIV, live,	90672
intranasal use	70072
Influenza virus vaccine, trivalent, derived from	90673
recombinant DNA ±RIV3, hemagglutnin ±HA	
protein only, preservative and antibiotic free, for	
intramuscular use	
Influenza virus vaccine, quadrivalent ±ccIIV4,	90674
derived from cell cultures, subunit, preservative	
and antibiotic free, 0.5 mL dosage, for	
intramuscular use	00.675
Rabies vaccine, for intramuscular use	90675
Rabies vaccine, for intramuscular use	90675
Rabies vaccine, for intramuscular use	90675
Rabies vaccine, for intradermal use	90676
Rotavirus vaccine, pentavalent, 3 dose schedule,	90680
live, for oral use	
Rotavirus vaccine, human, attenuated, 2 dose	90681
schedule, live, for oral use	

The authors provided this information as a supplement to their article.

influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to individuals 3 years of age and older, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, ive, oral Typhoid vaccine, ive, oral Typhoid vaccine, heat- and phenol-inactivated ±ViCPs, for intramuscular use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTaP, for intramuscular use Diphtheria, and tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use Diphtheria, and tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children	90685
preservative free, when administered to individuals 3 years of age and older, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, end hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenzae type b PRP-OMP conjugate vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use	6-35 months of age, for intramuscular us	
individuals 3 years of age and older, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide #ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated #H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated #DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, entramuscular use Diphtheria, tetanus toxoids, and hepatitis B vaccine #DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated #DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine #DTaP, for se in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine #DTaP, for intramuscular use		90686
intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, encorried, inactivated poliovirus vaccine, encorried, inactivated poliovirus vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza type B, and poliovirus vaccine, inactivated ±DTaP- Hib -IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use		
Influenza virus vaccine, quadrivalent, split virus, when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, live, oral Typhoid vaccine, live, oral Typhoid vaccine, keat- and phenol-inactivated ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use	•	
when administered to children 6-35 months of age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use	intramuscular use	
age, for intramuscular use Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90687
Influenza virus vaccine, quadrivalent, split virus, when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	when administered to children 6-35 months of	
when administered to individuals 3 years of age and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	ŭ	
and older, for intramuscular use Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90688
Typhoid vaccine, live, oral Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	when administered to individuals 3 years of age	
Typhoid vaccine, Vi capsular polysaccharide ±ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	and older, for intramuscular use	
#ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated #H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated #DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine #DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated #DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine #DTP, for intramuscular use	Typhoid vaccine, live, oral	90690
#ViCPs, for intramuscular use Typhoid vaccine, heat- and phenol-inactivated #H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated #DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine #DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated #DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine #DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine #DTP, for intramuscular use	Typhoid vaccine, Vi capsular polysaccharide	90691
Typhoid vaccine, heat- and phenol-inactivated ±H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
#H-P, for subcutaneous or intradermal use Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	Typhoid vaccine, heat- and phenol-inactivated	90692
Typhoid vaccine, acetone-killed, dried ±AKD, for subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
subcutaneous use ±U.S. military Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90693
Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenzar Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
vaccine and poliovirus vaccine, inactivated ±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenzar Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90696
±DTaP-IPV, when administered to children 4 years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
years through 6 years of age, for intramuscular use Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	_	
Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	Diphtheria, tetanus toxoids, acellular pertussis	90697
Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine ±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	_	
±DTaP-IPV-Hib-HepB, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	conjugate vaccine, and hepatitis B vaccine	
Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	±DTaP-IPV-Hib-HepB, for intramuscular use	
poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90698
poliovirus vaccine, inactivated ±DTaP - Hib - IPV, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	•	
Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	IPV, for intramuscular use	
vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use	Diphtheria, tetanus toxoids, and acellular pertussis	90700
Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
Diphtheria, tetanus toxoids, and acellular pertussis vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
vaccine ±DTaP, for use in individuals younger than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		90700
than seven years, for intramuscular use Diphtheria, tetanus toxoids, and whole cell pertussis vaccine ±DTP, for intramuscular use		
pertussis vaccine ±DTP, for intramuscular use		
pertussis vaccine ±DTP, for intramuscular use		90701
	*	
Dipliniona and examps toxonos and adsorbed for 70/02	Diphtheria and tetanus toxoids ±DT adsorbed for	90702
use in individuals younger than seven years, for	use in individuals younger than seven years, for	
intramuscular use	_ · · · · · · · · · · · · · · · · · · ·	
Tetanus toxoid adsorbed, for intramuscular use 90703	Tetanus toxoid adsorbed, for intramuscular use	90703

The authors provided this information as a supplement to their article.

Mumps virus vaccine, live, for subcutaneous use	90704
Measles virus vaccine, live, for subcutaneous use	90705
Rubella virus vaccine, live, for subcutaneous use	90706
Measles, mumps and rubella virus vaccine	90707
±MMR, live, for subcutaneous use	
Measles and rubella virus vaccine, live, for	90708
subcutaneous use	
Measles, mumps, rubella, and varicella vaccine ±MMRV, live, for subcutaneous use	90710
Poliovirus vaccine, ±any type±s ±OPV, live, for oral use	90712
Poliovirus vaccine, inactivated, ±IPV, for	90713
subcutaneous or intramuscular use	
Tetanus and Diphtheria, adsorbed	90714
Typhoid vaccine	90714
Tetanus and diphtheria toxoids ±Td adsorbed, preservative free, for use in individuals seven years or older, for intramuscular use	90714
Tetanus, diphtheria toxoids and acellular pertussis vaccine ±Tdap, for use in individuals 7 years or older, for intramuscular use	90715
Varicella virus vaccine, live, for subcutaneous use	90716
Yellow fever vaccine, live, for subcutaneous use	90717
Tetanus and diphtheria toxoids ±Td adsorbed for use in individuals seven years or older, for intramuscular use	90718
Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus influenza B vaccine ±DTP-Hib, for intramuscular use	90720
Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine ±DTaP-Hib, for intramuscular use	90721
Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated ±DTaP-HepB-IPV, for intramuscular use	90723
Influenza virus vaccine	90724
Cholera vaccine for injectable use	90725
Rabies vaccine	90726
Plague vaccine, for intramuscular use	90727
BCG vaccine	90728
Hepatitis A vaccine	90730

The authors provided this information as a supplement to their article.

Hepatitis B vaccine	90731
Pneumococcal polysaccharide vaccine, 23-valent,	90732
adult or immunosuppressed patient dosage, for	
use in individuals 2 years or older, for	
subcutaneous or intramuscular use	
Meningococcal polysaccharide vaccine ±any	90733
group±s, for subcutaneous use	
Meningococcal conjugate vaccine, serogroups A,	90734
C, Y and W-135 ±tetravalent, for intramuscular	
use	
Meningococcal conjugate vaccine, serogroups A,	90734
C, Y and W-135 ±tetravalent, for intramuscular	
use	
Japanese encephalitis virus vaccine, for	90735
subcutaneous use	
Zoster ±shingles vaccine, live, for subcutaneous	90736
injection	
Hemophilus influenza B	90737
Japanese encephalitis virus vaccine, inactivated,	90738
for intramuscular use	
Hepatitis B, adult dosage ±2 dose schedule, for	90739
intramuscular use	
Hepatitis B vaccine, dialysis or	90740
immunosuppressed patient dosage ±3 dose	
schedule, for intramuscular use	
Immunization, passive; immune serum globulin,	90741
human ±ISG	
Hepatitis B vaccine, adolescent ±2 dose schedule,	90743
for intramuscular use	
Hepatitis B vaccine, pediatric/adolescent dosage	90744
±3 dose schedule, for intramuscular use	
Hepatitis B vaccine, adolescent/high risk infant	90745
dosage, for intramuscular use	
Hepatitis B vaccine, adult dosage, for	90746
intramuscular use	
Hepatitis B vaccine, dialysis or	90747
immunosuppressed patient dosage ±4 dose	
schedule, for intramuscular use	
Hepatitis B and Hemophilus influenza b vaccine	90748
±HepB-Hib, for intramuscular use	
Modified from Centers for Disease Central and Prov	CDT 1 1. CVVV 1 A '1.11

Modified from Centers for Disease Control and Prevention. CPT codes mapped to CVX codes. Available at: https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt. Retrieved March 1, 2017.

Swartz JJ, Hainmueller J, Lawrence J, Rodriguez MI. Expanding prenatal care to unauthorized immigrant women and the effects on infant health. Obstet Gynecol 2017; 130.

The authors provided this information as a supplement to their article.

Appendix 9. Descriptive Statistics for Covariates by Insurance Group

		Emergency	
Insurance:	Emergency Medicaid (EM)	Medicaid Plus Prenatal (EMP)	Medicaid
Year of pregnancy	2007.09	2012.07	2009.35
	(2.87)	(2.18)	(3.67)
Age at delivery (years, 12-50)	26.97	28.75	25.35
	(5.80)	(5.94)	(5.57)
Gravidity (count)	1.40	1.82	1.60
	(0.68)	(0.95)	(0.98)
Ethnicity: Hispanic (0/1)	0.80	0.77	0.13
	(0.40)	(0.42)	(0.33)
Ethnicity: Not Hispanic (0/1)	0.08	0.23	0.80
	(0.27)	(0.42)	(0.40)
Ethnicity: Unknown (0/1)	0.12	0.00	0.07
	(0.32)	(0.03)	(0.26)
Race: White (0/1)	0.15	0.23	0.74
	(0.36)	(0.42)	(0.44)
Race: Asian or Pacific islander (0/1)	0.03	0.06	0.02
	(0.16)	(0.23)	(0.14)
Race: Black (0/1)	0.00	0.01	0.04
	(0.07)	(0.12)	(0.19)
Race: Hispanic (0/1)	0.06	0.00	0.00
	(0.23)	(0.00)	(0.06)
Race: American Indian (0/1)	0.00	0.00	0.02
	(0.04)	(0.04)	(0.15)
Race: Other (0/1)	0.76	0.69	0.17
	(0.43)	(0.46)	(0.38)

The authors provided this information as a supplement to their article.

^{©2017} American College of Obstetricians and Gynecologists.



Appendix 10. Effect of Emergency Medicaid Plus Prenatal on Mortality of Infants

	DID Model	Triple DID Model
Outcome:	Effect 95 % CI	Effect 95 % CI
Death in first 365 days (per 1,000)	-1.01 [-1.42; -0.60]	-1.40 [-1.99; -0.82]
Death in first 730 days (per 1,000)	-1.19 [-1.66; -0.73]	-1.43 [-2.10; -0.77]
Death in first 1095 days (per 1,000)	-1.06 [-1.63; -0.48]	-1.32 [-1.90; -0.73]

Effect estimates from difference-in-differences model $\pm DID$ and triple differences model $\pm Triple$ DID model with robust 95% confidence intervals $\pm clustered$ by county in parentheses. Low birth weight- 2499 g or less- very low birth weight- 1500 g and less- extremely low birth weight- 1000 g or less. Emergency room visits include urgent care. All models include county fixed effects, month fixed effects, county specific time-trends, and covariates $\pm age$ polynomial, race fixed effects, ethnicity fixed effects, and no. of pregnancy fixed effects. N = 47692 for DID models and N = 213746 for Triple DID models.

Appendix 11. Check for Compositional Shifts: Effect of Emergency Medicaid Plus Prenatal on Covariates

	DID Model	Triple DID Model
Outcome:	Effect 95 % CI	Effect 95 % CI
Age at delivery (years, 12-50)	-0.06 [-0.30; 0.17]	0.41 [0.25; 0.58]
Gravidity (count)	0.00 [-0.04; 0.04]	0.03 [-0.04; 0.10]
Ethnicity: Hispanic (0/1)	-0.02 [-0.03; 0.00]	-0.02 [-0.05; 0.01]
Ethnicity: Not Hispanic (0/1)	0.01 [-0.00; 0.03]	0.00 [-0.02; 0.03]
Ethnicity: Unknown (0/1)	0.00 [-0.00; 0.01]	0.01 [-0.00; 0.03]
Race: White (0/1)	0.02 [0.00; 0.03]	0.09 [0.03; 0.15]
Race: Asian or Pacific islander (0/1)	-0.00 [-0.01; 0.00]	0.02 [0.01; 0.02]
Race: Black (0/1)	-0.00 [-0.00; 0.00]	-0.03 [-0.05; -0.00]
Race: Hispanic (0/1)	0.00 [-0.00; 0.01]	-0.04 [-0.06; -0.03]
Race: American Indian (0/1)	0.00 [-0.00; 0.00]	0.00 [-0.00; 0.01]
Race: Other (0/1)	-0.02 [-0.03; -0.00]	-0.03 [-0.07; -0.00]

Effect estimates from difference-in-differences model $\pm DID$ and triple differences model $\pm Triple$ DID model with robust 95% confidence intervals $\pm clustered$ by county in parentheses. All models include county fixed effects, month fixed effects, and county specific time- trends. Gravidity is defined as the number of pregnancies identified between 2003-2015. N = 47692 for DID models and N=213746 for Triple DID models.

Appendix 12. Fisher Exact Test for Effect of EMP on Infant Mortality ±365 Days

Period:	Pre		Post		Total	
Alive at 365 days	34522	99.89%	13125	99.96%	47647	99.91%
Dead at 365 days	37	0.11%	5	0.04%	42	0.09%
Total	34559	100.00%	13130	100.00%	47689	100.00%
Fisher's exact pval:	0.024					

Appendix 13. Fisher Exact Test for Effect of EMP on Infant Mortality ±730 Days

Period:	Pre		Post		Total	
Alive at 730 days	34519	99.88%	13124	99.95%	47643	99.90%
Dead at 730 days	40	0.12%	6	0.05%	46	0.10%
Total	34559	100.00%	13130	100.00%	47689	100.00%
Fisher's exact pval:	0.031					

Appendix 14. Fisher Exact Test for Effect of EMP on Infant Mortality ±1095 Days

Period:	Pre		Post		Total	
Alive at 1095 days	34517	99.88%	13122	99.94%	47639	99.90%
Dead at 1095 days	42	0.12%	8	0.06%	50	0.10%
Total	34559	100.00%	13130	100.00%	47689	100.00%
Fisher's exact pval:	0.080					

Appendix 15. Fisher Exact Test for Infant Mortality Pre vs Post EMP on Medicaid Sample ±365

Days

Period:	Pre		Post		Total	
Alive at 365 days	102365	99.89%	63467	99.83%	165832	99.87%
Dead at 365 days	109	0.11%	110	0.17%	219	0.13%
Total	102474	100.00%	63577	100.00%	166051	100.00%
Fisher's exact pval:	0.000					

Appendix 16. Fisher Exact Test for Infant Mortality Pre vs Post EMP on Medicaid Sample ±730

Days

Period:	Pre		Post		Total	
Alive at 730 days	102354	99.88%	63459	99.81%	165813	99.86%
Dead at 730 days	120	0.12%	118	0.19%	238	0.14%
Total	102474	100.00%	63577	100.00%	166051	100.00%
Fisher's exact pval:	0.000					

Appendix 17. Fisher Exact Test for Infant Mortality Pre vs Post EMP on Medicaid Sample ± 1095 Days

Period:	Pre		Post		Total	
Alive at 1095 days	102343	99.87%	63457	99.81%	165800	99.85%
Dead at 1095 days	131	0.13%	120	0.19%	251	0.15%
Total	102474	100.00%	63577	100.00%	166051	100.00%
Fisher's exact pval:	0.002					

References

- Hornbrook, M. C. *et al.* Development of an Algorithm to Identify Pregnancy Episodes in an Integrated Health Care Delivery System. *Health Serv. Res.* 42, 908–927 ±2007.
- Bright Future and Preventive Medicine Coding Fact Sheet. Available at: https://www.aap.org/en-us/professional-resources/practice-transformation/getting-paid/Coding-at-the-AAP/Pages/Bright-Futures-and-Preventitive-Medicine-Coding-Fact-Sheet.aspx. ±Accessed: 1st March 2017